Email This Article
Subpoena May Spoil Genentech's Earnings Party
By
Robert Steyer
10/06/04 - 04:13 PM EDT
The company has high hopes for two new drugs, but a probe into Rituxan may divert investors' attention.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.




View Directory